iBio (IBIO) 10-Q 2012 Q3 Quarterly report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2012

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number 001-35023

iBio, Inc.

(Exact name of small business registrant in its charter)

Delaware	26-2797813
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
9 Innovation Way, Suite 100, Newark, DE	19711
(Address of principal executive offices)	(Zip Code)

(302) 355-0650
(Registrant’s telephone number, including Area Code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yesx Noo

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yesx Noo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filero	Accelerated filero	Non-accelerated filero	Smaller reporting companyx
Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
	Yeso	Nox
The number of shares outstanding of each of the issuer’s class of common stock, as of the latest practicable date:
Class		Outstanding at May 15, 2012
Common Stock, $0.001 par value		47,767,095 Shares

iBio, Inc.
FORM 10-Q
For the Three and Nine Month Periods Ended March 31, 2012

INDEX

		Page
PART I	FINANCIAL INFORMATION
Item 1	Financial Statements
	Condensed Balance Sheets as of March 31, 2012 (unaudited) and June 30, 2011	1
	Condensed Statements of Operations (unaudited) for the three and nine months ended March 31, 2012 and 2011	2
	Condensed Statement of Stockholders’ Equity (unaudited) for the nine months ended March 31, 2012	3
	Condensed Statements of Cash Flows (unaudited) for the nine months ended March 31, 2012 and 2011	4
	Notes to Condensed Financial Statements (unaudited)	5-12
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4	Controls and Procedures	17
PART II	OTHER INFORMATION
Item 1	Legal Proceedings	17
Item 1A	Risk Factors	17
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3	Defaults upon Senior Securities	18
Item 4	Mine Safety Disclosures	18
Item 5	Other Information	18
Item 6	Exhibits	18
Signatures		19

Part 1 Financial Information
Item 1 Financial Statements

iBio, Inc.
Condensed Balance Sheets

		As of
		March 31, 2012			June 30, 2011
		(Unaudited)			(Note A)
	Assets
Current assets:
Cash		$	6,724,096		$	2,843,300
Accounts receivable			371,755			344,085
Prepaid expenses			205,069			763,583
Other current assets			376,879			349,210
Total current assets			7,677,799			4,300,178
Fixed assets, net			6,072			8,412
Intangible assets, net			2,971,893			3,027,239
Total assets		$	10,655,764		$	7,335,829
	Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	2,182,401		$	2,895,359
Accrued expenses			303,891			56,059
Derivative instrument liability			1,314,937			4,187,769
Total liabilities			3,801,229			7,139,187
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares outstanding			—			—
Common stock, $0.001 par value, 100,000,000 shares authorized, 47,767,095 and 32,382,095 issued and outstanding as of March 31, 2012 and June 30, 2011, respectively			47,767			32,382
Additional paid-in capital			36,781,966			25,826,203
Accumulated deficit			(29,975,198	)		(25,661,943	)
Total stockholders’ equity			6,854,535			196,642
Total liabilities and stockholders’ equity		$	10,655,764		$	7,335,829

The accompanying notes are an integral part of these unaudited condensed financial statements.

1

iBio, Inc.
Condensed Statements of Operations
(Unaudited)

	Three Months Ended March 31,						Nine Months Ended March 31,
	2012			2011			2012			2011
Revenues	$	371,755		$	175,995		$	925,935		$	175,995
Operating expenses:
Research and development		1,307,246			1,137,435			3,926,206			1,914,514
General and administrative		1,246,319			1,927,026			4,180,209			4,386,070
		2,553,565			3,064,461			8,106,415			6,300,584
Operating loss		(2,181,810	)		(2,888,466	)		(7,180,480	)		(6,124,589	)
Other income (expense):
Interest income		4,975			4,989			7,181			9,186
Interest expense		(17,920	)		(7,692	)		(44,296	)		(33,743	)
Royalty income		14,445			4,156			31,508			14,360
Change in the fair value of derivative instrument liability		(918,428	)		(144,313	)		2,872,832			(4,424,932	)
		(916,928	)		(142,860	)		2,867,225			(4,435,129	)
Net loss	$	(3,098,738	)	$	(3,031,326	)	$	(4,313,255	)	$	(10,559,718	)
Net loss per common share - basic and diluted	$	(0.07	)	$	(0.09	)	$	(0.12	)	$	(0.35	)
Weighted average common shares outstanding - basic and diluted		45,715,762			32,338,587			36,761,767			30,499,090

The accompanying notes are an integral part of these unaudited condensed financial statements.

2

iBio, Inc.
Condensed Statement of Stockholders’ Equity
For The Nine Months Ended March 31, 2012
(Unaudited)

	Common Stock
					Additional Paid-In Capital		Accumulated Deficit
	Shares		Amount							Total
Balance, June 30, 2011		32,382,095	$	32,382	$	25,826,203	$	(25,661,943	)	$	196,642
Issuance of stock and warrants, net of expenses		15,385,000		15,385		9,020,463		—			9,035,848
Share-based compensation		—		—		1,935,300		—			1,935,300
Net loss		—		—		—		(4,313,255	)		(4,313,255	)
Balance, March 31, 2012		47,767,095	$	47,767	$	36,781,966	$	(29,975,198	)	$	6,854,535

The accompanying notes are an integral part of these unaudited condensed financial statements.

3

iBio, Inc.
Condensed Statements of Cash Flows
(Unaudited)

	Nine Months Ended March 31,
	2012			2011
Cash flows from operating activities:
Net loss	$	(4,313,255	)	$	(10,559,718	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in the fair value of derivative instrument liability		(2,872,832	)		4,424,932
Depreciation and amortization		243,263			283,703
Share-based compensation expense		1,935,300			2,746,207
Share-based compensation expense included in accrued expenses		70,752			—
Changes in operating assets and liabilities:
Increase in accounts receivable		(27,670	)		(175,995	)
Decrease (increase) in prepaid expenses and other current assets		530,845			(101,075	)
Decrease in accounts payable		(712,958	)		(905,573	)
Increase in accrued expenses		177,080			47,886
Net cash used in operating activities		(4,969,475	)		(4,239,633	)
Cash flows from investing activities:
Additions to intangible assets		(184,690	)		(199,801	)
Purchase of fixed assets		(887	)
Net cash used in investing activities		(185,577	)		(199,801	)
Cash flows from financing activities:
Net proceeds from the sale of common stock and warrants, net of expenses		9,035,848			7,235,644
Exercise of warrants					130,000
Net cash provided by financing activities		9,035,848			7,365,644
Net increase in cash		3,880,796			2,926,210
Cash - Beginning of period		2,843,300			909,832
Cash - End of period	$	6,724,096		$	3,836,142
Supplemental disclosures of non-cash investing activities:
Issuance of common stock pursuant to the anti-dilution provisions of the August 2008 financing				$	20

The accompanying notes are an integral part of these unaudited condensed financial statements.

4

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

NOTE A - BUSINESS

iBio, Inc. (“iBio” or the “Company”) is a biotechnology company focused on commercializing its proprietary technology, the iBioLaunch™ platform, for biologics including vaccines and therapeutic proteins. The Company’s strategy is to promote its commercial products through collaborations and license arrangements. iBio’s strategy is to receive upfront license fees, milestone revenues, service revenues and royalties on end products. The Company believes its technology offers the opportunity to develop products that might not otherwise be commercially feasible, and to work with both corporate and government clients to reduce their costs during product development and meet their needs for low-cost, high-quality biologics manufacturing systems. The Company’s near-term focus is to establish business arrangements for use of its technology by licensees for the development and production of products for both therapeutic and vaccine uses.

Basis of Presentation

The accompanying financial information as of March 31, 2012 and for the three and nine months ended March 31, 2012 and 2011, is unaudited and includes all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to state fairly the condensed financial information set forth therein in accordance with accounting principles generally accepted in the United States of America. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been omitted as permitted by regulations of the Securities and Exchange Commission. The interim results are not necessarily indicative of results to be expected for the full fiscal year. The condensed balance sheet amounts as of June 30, 2011 were derived from the audited financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements for the year ended June 30, 2011 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

The Company has incurred losses and negative cash flows from operations since the spinoff from its Former Parent in August 2008. As of March 31, 2012, the Company had an accumulated deficit of approximately $29,975,000 and cash used from operations for the nine months ended March 31, 2012 and 2011 was approximately $4,969,000 and $4,240,000, respectively. The Company has historically financed its activities through the sale of common stock and warrants. To date, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ platform, advancing intellectual property, product candidate development, and general and administrative activities.

iBio believes it has the financial capabilities to meet its current obligations. In addition, the Company estimates the cash on hand as of March 31, 2012 of approximately $6,724,000 will be adequate to fund its operations until the second calendar quarter of 2013. The Company plans to fund its further development and commercialization through licensing and partnering arrangements, which may include milestone receipts and royalties, and/or the sale of equity securities or debt. The Company cannot be certain that such funding will be available on acceptable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. In January 2012, the Company raised net proceeds of approximately $9,036,000 (see Note C). Further, if additional funds are raised by the issuance of equity or debt, additional securities may have powers, designations, preferences or rights senior to its currently outstanding securities. If the Company is unable to raise funds when required or on acceptable terms, it may have to: a) significantly delay, scale back, or discontinue the development and/or commercialization of one or more product candidates; b) seek collaborators for product candidates at an earlier stage than would otherwise be desirable and/or on terms that are less favorable than might otherwise be available; or c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize itself and d) possibly cease operations.

In addition to the normal risks associated with a new business venture, there can be no assurance that any of the Company’s further research and development will be successfully completed or that any product will be approved or commercially viable.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with Food and Drug Administration (“FDA”) and other governmental regulations and approval requirements.

Significant Accounting Policies

The Company’s significant accounting policies are described in Note B to its audited Financial Statements included in its June 30, 2011 Form 10-K.There have been no significant changes to these policies or changes in accounting pronouncements during the three and nine months ended March 31, 2012. In October and November 2011, the Board of Directors modified the terms of previously issued options to eliminate the ninety days vesting period cancellation provision, thus permitting an option holder, upon termination without cause, to exercise the vested portion of an option post-termination up to ten years after the grant date. Current period option awards granted also include these terms. See Note C for compensation expense relating to such modification. Through September 30, 2011, in its model for estimating the fair value of option awards, the Company used the simplified method of estimating the expected term for share-based compensation. During the three and six months ended December 31, 2011 and thereafter, the Company ceased using the simplified method and now estimates the expected term for each award will approximate its contractual term. The Company uses its historical stock price volatility consistent with the expected term of grant as the basis for its expected volatility assumption. The risk-free interest rate is based upon the yield of U.S. Treasury securities consistent with the expected term of the option. The dividend yield assumption is based on the Company’s history of zero dividend payouts and expectation that no dividends will be paid in the foreseeable future.

5

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

Loss Per Share

Basic earnings (loss) per share is computed by dividing the net income (loss) allocated to common shares by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect the additional potential dilution that could occur if options or warrants were exercised or converted into common stock, using the treasury stock method. Since the Company incurred a net loss in each of those periods, diluted loss per share for the three and nine months ended March 31, 2012 and 2011, respectively were the same as basic loss per share. There were 26,417,463 and 12,078,607 options and warrants for the three and nine months ended March 31, 2012 that were excluded from the calculation of dilutive earnings per shares since they were anti-dilutive.

The following table summarizes the number of common shares excluded from the calculation of weighted average common shares outstanding for the three and nine months ended March 31, 2012 and 2011, respectively:

	Three and nine months ended March 31,
	2012		2011
Stock options		5,476,667		4,130,000
Warrants		20,940,796		7,948,607
Total		26,417,463		12,078,607

Fair Value of Financial Instruments

The Company’s financial instruments primarily include cash, accounts receivable, other current assets, accounts payable, and a derivative liability. Due to the short-term nature of cash, accounts receivable, current assets, accounts payable, and the derivative instrument liability relating to a warrant with anti-dilution protection, the carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company categorizes its derivative financial instrument liability in Level 2 of the hierarchy. The derivative instrument liability relating to a warrant with down round protection is valued using the Black-Scholes option pricing model, using assumptions consistent with the determination of fair value. The fair value of the derivative financial instrument liability is based principally on Level 2 inputs. For this liability, the Company developed its own assumptions based on observable inputs or available market data to support the fair value.

6

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheets at March 31, 2012 and June 30, 2011:

	Fair value measurement at reporting date using
	Quoted prices In active Market for Identical assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
At March 31, 2012
Liabilities:
Recurring
Derivative financial instrument liability - related to a warrant with anti-dilution protection	$	—	$	1,314,937	$	—	$	1,314,937

	Quoted prices In active Market for Identical assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
At June 30, 2011
Liabilities:
Recurring
Derivative financial instrument liability	$	—	$	4,187,769	$	—	$	4,187,769

The above valuations were determined using Level 2 inputs. The reconciliation of the derivative financial instrument liability measured at fair value on a recurring basis using observable inputs (Level 2) is as follows:

Balance, June 30, 2011 and 2010, respectively	$	4,187,769		$	1,714,084
Change in fair value of derivative financial instrument liability		(2,872,832	)		4,424,932
Balance, March 31, 2012 and 2011, respectively,	$	1,314,937		$	6,139,016

The fair value of the derivative financial instrument liability is determined using the Black-Scholes option pricing model and is affected by changes in inputs to that model including the Company’s stock price, expected stock price, volatility, dividend yield, the contractual term, and the risk-free interest rate.

The assumptions made in calculating the fair value of these derivative instruments as of March 31, 2012 and 2011 and June 30, 2011 were as follows:

	��
		March 31, 2012	June 30, 2011	March 31, 2011
Risk-free interest rate		0.2%	0.4%	1.1%
Dividend yield		None	None	None
Volatility		98.9%	96.7%	133.0%
Remaining contractual term (in years)		1.4	2.2	2.4

7

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

NOTE B – INTANGIBLE ASSETS

Intangible assets consist of the following:

	March 31, 2012			June 30, 2011
Intellectual property	$	3,100,000		$	3,100,000
Patents		1,718,056			1,533,366
		4,818,056			4,633,366
Accumulated amortization - intellectual property		(1,270,485	)		(1,153,710	)
Accumulated amortization – patents		(575,678	)		(452,417	)
		(1,846,163	)		(1,606,127	)
Net	$	2,971,893		$	3,027,239

Intellectual property consists of technology for producing targeted proteins in plants for the development and manufacture of novel vaccines and therapeutics for humans and also certain novel product compositions and uses. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over a period from eighteen to twenty-three years and patents over ten years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company’s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. There was no impairment during the three and nine months ended March 31, 2012.

Amortization expense for intangible assets is recorded utilizing the straight-line method, was included in general and administrative expenses, and approximated $81,000 and $95,000, for the three months ended March 31, 2012 and 2011, respectively. Amortization expense for the nine months ended March 31, 2012 and 2011 was approximately $240,000 and $281,000 respectively.

NOTE C – STOCKHOLDERS’ EQUITY

January 2012 Units

On January 13, 2012, the Company raised net proceeds of approximately $9,036,000 after offering expenses of approximately $964,000 by issuing 15,385,000 shares of common stock at $0.65 per share and warrants to purchase 11,538,750 shares of common stock. The Company paid to the underwriter a discount expense of approximately $700,000. The common stock and warrants were sold together as units (the “Units”), each Unit consisting of one share of common stock and 0.75 of one warrant to purchase one share of common stock. Each warrant has an exercise price of $0.88 per share and will be exercisable after the first anniversary of issuance and will expire on the second anniversary date of issuance. In the event the Company issues rights, options or warrants to holders of its common stock, the exercise price of the warrants may be adjusted for the anti-dilutive effects of such an issuance. The Company used its effective registration statement on Form S-3 for this offering.

This equity offering triggered the anti-dilution provisions applicable to the August 2008 equity offering (see Note A – Fair Value of Financial Instruments relating to derivate instrument liability) and resulted in the following:

1)	Modification of the warrants issued to the investors in the August 2008 offering to provide for the purchase of an additional 1,353,439 shares of common stock and adjustment of the exercise prices as follows;
	a)	Warrants for the purchase of 1,400,449 shares of common stock at $2.68 per common share were revised to the purchase of 2,065,814 at $1.82 per share; and
	b)	Warrants for the purchase of 1,448,247 shares of common stock at $3.45 per common share were revised to the purchase of 2,136,321 shares of common stock at $2.34 per share.

8

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

Share-Based Compensation - Stock Options and Warrants

The Company accounts for options granted to employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Options and warrants granted to consultants and other non-employees are recorded at fair value as of the grant date and subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management deems the service obligation for future services has ceased.

On August 12, 2008, the Company adopted the iBioPharma, Inc. 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors, or external service providers. Under the provisions of the Plan, the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 10,000,000 shares. There are 4,523,333 options available for future issuance under the Plan. Options granted under the Plan may be either “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, or non-statutory stock options at the discretion of the Board of Directors and as reflected in the terms of the written option agreement. Options granted under the Plan during the three and nine months ended March 31, 2012 vest ratably at the end of each twelve-month period within either a three or five-year period from the date of grant, subject to certain conditions that result in acceleration of vesting or termination of the options. Previously granted options vest ratably at the beginning of each twelve-month period.

Share-based compensation expense was recorded as follows:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2012		2011		2012		2011
Research and development	$	58,475	$	105,277	$	81,662	$	377,797
General and administrative		553,473		1,248,974		1,924,390		2,368,410
Total	$	611,948	$	1,354,251	$	2,006,052	$	2,746,207

In November and December 2011, the Board of Directors modified the cancellation provision of previously issued options, permitting an option holder, upon termination without cause, to exercise the vested portion of an option post-termination up to ten years after the grant date. Current period option awards granted also include this provision. Through September 30, 2011, in its model for estimating the fair value of option awards, the Company used the simplified method of estimating the expected term for share-based compensation. During the three and six months ended December 31, 2011, the Company ceased using the simplified method and now estimates the expected term for each award to approximate its contractual term. The Company uses its historical stock price volatility consistent with the expected term of grant as the basis for its expected volatility assumption. The Company estimated the effect of the modification to be approximately $633,000. Such value was based upon the fair market value of the options prior to the modification and the fair market value after the modification. Accordingly, for the three and nine months ended March 31, 2012, the Company recorded a modification charge of approximately $59,000 and $510,000 respectively. The balance of $123,000 will be recorded over the remaining vesting period.

Summary of the changes in options outstanding during the nine months ended March 31, 2012 and the year ended June 30, 2011 is as follows:

9

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

	Number of Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2010		2,210,000		$	0.58		9.1	$	1,770,000
Granted		2,140,000		$	2.44
Outstanding at June 30, 2011 and expected to vest at June 30, 2011		4,350,000		$	1.49		8.7	$	6,112,000
Granted		1,160,000		$	1.80		9.6
Forfeited		(33,333	)	$	0.87
Outstanding at March 31, 2012 and expected to vest at March 31, 2012		5,476,667		$	1.56		8.1	$	1,234,000
Options exercisable at March 31, 2012		2,631,333		$	1.29		7.8	$	930,000

The weighted average fair value of options granted at the date of grant during the nine months ended March 31, 2012 and 2011 were $1.58 and $1.96 per share, respectively on the dates of grant using the Black-Scholes option-pricing model. Options granted and options required to be revalued each reporting period were calculated with the following assumptions:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2012		2011		2012		2011
Risk free interest rate		1.6% to 2.2%		1.5% to 2.7%		1.9% to 2.2%		0.3% to 3.6%
Dividend yield		Zero		Zero		Zero		Zero
Volatility		96.4% to 98.9%		133%		94.8% to 98.9%		98% to 133%
Range of expected option life (in years)		9.0 to 10.0		4.3 to 8.9		9.0 to 10.0		0.9 to 8.9

In October 2011, the Company issued 900,000 options to members of the Board of Directors and certain officers and 100,000 options to an employee to purchase shares of common stock at $1.96. These options vest between three to five years and expire in ten years. In addition, the Company issued 60,000 options to a member of the Board of Directors (see Note D).

In February 2012, the Company issued 100,000 options to an employee for the purchase of common stock at $0.77 per share.

A summary of the changes in warrants outstanding during the year ended June 30, 2011 and nine months ended March 31, 2012 is as follows:

	Number of Shares			Weighted Average Exercise Price Per Share
Outstanding at June 30, 2010		3,085,811		$	2.91
Granted (1)		7,973,020		$	2.41
Exercised		(95,000	)	$	1.54
Cancelled (1)		(3,015,224	)	$	3.08
Outstanding at June 30, 2011		7,948,607		$	2.37
Granted (1)		15,840,885		$	1.20
Cancelled (1)		(2,848,696	)	$	3.07
Outstanding at March 31, 2012		20,940,796		$	1.38
Exercisable at June 30, 2011		7,688,607		$	2.42
Exercisable at March 31, 2012		20,860,796		$	1.38

10

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

(1)	Includes a modification to 2,715,224 and 2,848,696 warrants during the year ended June 30, 2011 and for the nine months March 31, 2012, respectively, to purchase common stock pursuant to the terms of the warrant agreement from the August 2008 offering due to the anti-dilution provisions. The August 2008 warrants expire in August 2013.
	In October 2011, the Company issued 100,000 warrants to purchase common stock at $2.00 per share to a consultant for investor relations services. The warrant has a term for two years and the fair market value at the date of grant was $0.71 per share using the Black-Scholes option-pricing model.

NOTE D - RELATED PARTY TRANSACTIONS

1)	The Company has a license agreement that earned royalties of approximately $14,000 and $4,000 during the three months ended March 31, 2012 and 2011, respectively. A stockholder of the Company is an officer of the licensee. The Company earned royalties of approximately $32,000 and $14,000 during the nine months ended March 31, 2012 and 2011, respectively.
2)	During the three and nine months ended March 31, 2012, the Company had three services arrangements with the Center for Molecular Biotechnology of Fraunhofer USA, Inc. (“FhCMB”) for research and development.
	A)	In 2003, the Company entered into a Technology Transfer Agreement, as amended (“TTA”) which requires FhCMB to provide the Company with research and development services related to the commercialization of the Technology and allows FhCMB to apply the Technology to the development and production of certain vaccines for use in developing countries as defined in the agreement. The most recent amendment to the TTA requires: 1) the Company to make payments to FhCMB of $2,000,000 per year for five years, aggregating $10,000,000, for such services beginning in November 2009; and 2) FhCMB to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology. Additionally, under the terms of the TTA and for a period of fifteen years: 1) the Company shall pay FhCMB a defined percent (per the agreement) of all receipts derived by the Company from sales of products produced utilizing the Technology and a defined percentage (per the agreement) of all receipts derived by the Company from licensing the Technology to third parties with an overall minimum annual payment of $200,000 beginning with the twelve months ended December 2010; and 2) FhCMB shall pay the Company a defined percentage (per the agreement) of all receipts from sales, licensing, or commercialization of the Technology in developing countries as defined in the agreement. All new intellectual property invented by FhCMB during the period of the TTA is owned by and is required to be transferred to iBio.
	B)	In December 2010, the Company and FhCMB entered into a $1,660,000 research services agreement to evaluate gene expression and protein production, focused on a series of product candidates, using the iBioLaunch platform.
	C)	In March 2011, the Company and FhCMB entered into a $432,000 research services agreement for the evaluation of the mechanism of immune-potentiating activity of lichenase (LicKM), which is a thermostable bacterial enzyme used as a carrier molecule for vaccine antigens. The value of lichenase is as an immunomodulator. Fraunhofer completed their research during the nine months ended March 31, 2012 and the Company recorded the entire cost of the agreement as of March 31, 2012.
	Below are expenses recorded with transactions associated with FhCMB for the three and nine months ended March 31, 2012 and 2011 and amounts included in the balance sheet accounts as of March 31, 2012 and June 30, 2011, respectively.

	Three Months Ended March 31,				Nine Months Ended March 31,
	2012		2011		2012		2011
Research and development expense	$	1,034,000	$	866,000	$	3,422,000	$	1,200,000
Royalty expense		50,000		50,000		150,000		150,000

	As of March 31, 2012		As of June 30, 2011
Prepaid expenses and other current assets	$	816,000	$	760,000
Accounts payable and accrued expenses		1,746,000		2,360,000

11

iBio, Inc.
Notes to Condensed Financial Statements (Unaudited)

3)	On February 1, 2012, the Company entered into a consulting agreement with a member of the board of directors, primarily for business development. The agreement is for six months at $15,000 per month and 60,000 options to purchase common stock at $0.93 per share. These options vest in six equal monthly installments of 10,000 and expire in ten years.
4)	On March 1, 2012, the Company entered into a consulting agreement with an executive officer of FhCMB to be the Company’s Scientific Advisor who was the former Chief Scientific Officer (CSO) of iBio effective February 29, 2012. As compensation, 300,000 unvested options that the former CSO had were allowed to continue to vest in accordance with the original terms of his option award. The fair market value of this non-employee option award at the date of grant for the unvested warrants was $243,000, and will continue to be amortized over the vesting terms. The initial option grant of 500,000 options to purchase common stock was granted on February 25, 2010 with an exercise price of $0.87 per share that expires in ten years. This option vests ratably on January 1, 2011and four subsequent anniversary dates.
5)	The Company entered into an agreement with a vendor, whose minority stockholder is the President of the Company. The vendor performs laboratory feasibility analyses of gene expression and protein purification and also preparation of research samples. The expense for the three and nine months is approximately $119,000.

Item 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read together with the financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding iBio’s expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K for the year ended June 30, 2011.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. iBio disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

Overview

iBio, Inc. (“iBio” and the “Company”) is a biotechnology company focused on commercializing its proprietary technology, the iBioLaunch™ platform, for biologics including vaccines and therapeutic proteins. Our strategy is to promote our technology through commercial product collaborations and license arrangements. We expect to share in the increased value our technology provides through upfront license fees, milestone revenues, service revenues, and royalties on end products. We believe our technology offers the opportunity to develop products that might not otherwise be commercially feasible, and to work with both corporate and government clients to reduce their costs during product development and meet their needs for low-cost, high-quality biologics manufacturing systems. Our near-term focus is to establish business arrangements for use of our technology by licensees for the development and production of products for both therapeutic and vaccine uses.

12

Vaccine candidates presently being advanced on our proprietary platform are applicable to newly emerging strains of H1N1 swine-like influenza, and H5N1 avian influenza, yellow fever, malaria, and anthrax. Therapeutic candidates presently being advanced on our proprietary platform include human alpha-galactosidase A for the treatment of Fabry disease, human C1 esterase inhibitor for the treatment of hereditary angioedema (HAE), human alpha-1 antitrypsin for treatment of disorders caused by a lack or deficiency of alpha-1 antitrypsin, a therapeutic vaccine for human papilloma virus (HPV), and several other therapeutic protein targets for which preliminary product feasibility has been demonstrated.

In order to attract appropriate licensees and increase the value of our share of such intended contractual arrangements, we engaged the Center for Molecular Biotechnology of Fraunhofer USA, Inc., or FhCMB, in 2003 to perform research and development activities to develop the platform and to create our first product candidate. We selected a plant-based influenza vaccine for human use as the product candidate to exemplify the value of the platform. Based on research conducted by FhCMB, our proprietary technology is applicable to the production of vaccines for any strain of influenza of H1N1 swine-like influenza. A Phase 1 clinical trial of a vaccine candidate for H1N1 influenza, based on iBio’s technology, was initiated in September 2010. We announced positive interim results in June 2011 and successful completion of the clinical trial in March 2012. The vaccine candidate demonstrated strong induction of dose correlated immune responses, with or without adjuvant, as assessed by virus microneutralization antibody assays and hemagglutination inhibition (“HAI”) responses. The vaccine was safe and well tolerated at all doses when administered with and without adjuvant.

In connection with the research and development agreement, FhCMB agreed to use its best efforts to obtain grants from governmental and non-governmental entities to fund additional development of our proprietary plant-based technology. Consequently, in addition to the funding we have provided, FhCMB has received funding from the Bill & Melinda Gates Foundation for development of various vaccines based upon our proprietary technology including an experimental vaccine for H5N1 avian influenza. A Phase 1 clinical trial of a vaccine candidate for H5N1 influenza, based on iBio’s technology, was initiated in December 2010 and is ongoing. We announced positive interim results in June 2011 and successful completion of the clinical trial in March 2012.

In addition to the platform and product development engagements, in 2006, the Company engaged FhCMB to create a prototype production module for products made through the use of the platform. The purpose of this engagement was to demonstrate the ease and economy with which platform-based products could be manufactured in order to attract potential licensees and increase the value of our share of such business arrangements. The prototype design, which encompasses the entire production process from the seeding through pre-infiltration plant growth, infiltration with agrobacteria, harvesting of plant tissue and purification of target proteins, was completed in May 2008. A pilot plant based upon this prototype was subsequently constructed in the FhCMB facility in Newark, Delaware. This pilot plant, and the equipment in it, are owned by FhCMB and have been validated for cGMP (current good manufacturing practice) production. It is anticipated that it will be used for cGMP production of protein targets for clinical trials of product candidates utilizing our platform technology.

In January 2011, we announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon our proprietary technology. Fiocruz/Bio-Manguinhos will invest $6.5 million to bring the first product candidate, a yellow fever vaccine, through a Phase I clinical trial. Yellow fever is a viral infection in the group of diseases known as hemorrhagic fevers. The virus is transmitted by mosquitoes, and is common in South America and sub-Saharan Africa. The disease, which causes fever, nausea and pain, varies in severity, but is frequently lethal when it progresses to bleeding or to liver damage. The World Health Organization has estimated that 200,000 unvaccinated people contract yellow fever each year, and approximately 30,000 die from the disease.

Development of the yellow fever vaccine candidate will be performed through a commercial collaboration among the Company, Fiocruz/Bio-Manguinhos, and FhCMB. The license covers the nations of Latin America, the Caribbean and Africa. The Company retains the right to sell the products developed under the license and collaboration agreement in any other territory with a royalty back to Fiocruz/Bio-Manguinhos. Bio-Manguinhos is a unit of the Oswaldo Cruz Foundation (Fiocruz), a central agency of the Ministry of Health of Brazil. Fiocruz/Bio-Manguinhos produces and develops immunobiological items to respond to public health demands. Its product line consists of vaccines, reagents and biopharmaceuticals. Fiocruz/Bio-Manguinhos is a leading company in the national export of human vaccines and a major participant in total export sales of the Brazilian pharmaceutical sector. Fiocruz/Bio-Manguinhos is one of the main producers of vaccines and diagnostics for infectious diseases in Latin America. Fiocruz/Bio-Manguinhos is a certified World Health Organization provider to United Nations agencies, and is a leading world manufacturer of yellow fever vaccine, which it has exported to over 60 countries.

The Company established non-commercial arrangements among the Company, certain government entities, a non-governmental organization (“NGO”) and FhCMB, pursuant to which the Company grants non-commercial rights to use its platform for the development and production by FhCMB of product candidates selected by the government entities and the NGO, in consideration for grants by the government entities and the NGO directly to FhCMB to fund such research and development.

Through (i) the Company/FhCMB contracts and (ii) the non-commercial arrangements described above (which we refer to collectively as the “business structure”), the Company retains ownership of the intellectual property and exclusive worldwide commercial rights in the fields of human health and veterinary influenza applications of the intellectual property. The Company licenses or otherwise grants

13

use rights (a) to government and NGO entities for not-for-profit applications of the intellectual property for the development or application for which they granted or were granted funding, and (b) to FhCMB for research purposes and applications in other fields.

This business structure helps the Company to enhance the value of commercial rights and the scope of applications of its platform technology. It also helps the Company demonstrate the validity and apparent value of the platform to parties to whom it will offer licenses or other business opportunities. Outsourcing our research and development work allows us to develop our product candidates, and thereby promote the value of our platform for licensing and product development purposes, without bearing the full risk and expense of establishing and maintaining our own research and development staff and facilities. FhCMB is engaged to perform research and development for the yellow fever vaccine project based on their expertise. The contract with FhCMB is expected to be $6.5 million. Service revenues and research expense under this arrangement commenced in January 2011. The amount of revenues recorded under this agreement and related research and development expenses for the three months ended March 31, 2012 and 2011 were approximately $372,000 and $176,000, respectively. The amount of revenues recorded under this agreement and related research and development expenses for the nine months ended March 31, 2012 and 2011 were approximately $926,000 and $176,000, respectively.

The Company’s platform technology is sometimes referred to as “iBioLaunch™ technology” or the “iBioLaunch™ platform,” and the category of this technology is sometimes referred to as “plant-based technology” or as a “plant-based platform.” The Company has exclusive control over, and the rights to ownership of, the intellectual property related to all human health and veterinary influenza applications of the plant-based technology developed by FhCMB. Current development projects include conducting proof-of-principle preclinical studies and conducting clinical studies of proprietary influenza vaccines. Many biotech drugs have been on the market long enough for patents on them to expire. Emerging opportunities for biosimilars (also known as biogenerics or follow-on biologics) create potential for our platform technology to be used by potential licensees to enter the market utilizing what the Company expects to be an economical production system. The Company is seeking commercial partners for this category of products and is unlikely to develop products in this category without the financial and marketing support of a commercial partner.

Our current product candidates are in the preclinical or early clinical stage of development and will require significant further research, development, clinical testing and regulatory clearances. They are subject to the risks of failure inherent in the development of products based on innovative technologies. These risks include, but are not limited to, the possibilities that any or all of these products will be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances; that these products, although effective, will be uneconomical to market; that third parties may now or in the future hold proprietary rights that preclude us from marketing them; or that third parties will market superior or equivalent products. Accordingly, we are unable to predict whether our research and development activities will result in any commercially viable products or applications. Further, due to the extended testing and regulatory review process of these product candidates required before marketing clearance can be obtained, we do not expect to be able to commercialize any for at least several years, either directly or through our current prospective partners or licensees. There can be no assurance that our product candidates will prove to be safe or effective or receive regulatory approvals that are required for commercial sale. Historically, in addition to the development of the platform technology described in the preceding paragraphs, the Company has also generated sales of nutritional supplements utilizing plants as sources of high-quality nutritional minerals.

The Company has a patented process for hydroponic growth of edible plants that causes them to accumulate high levels of important nutritional minerals such as chromium, selenium, iron and zinc. The Company utilized the services of various wholly-owned subsidiaries of our former parent company, Integrated BioPharma, Inc. (“Integrated BioPharma” or “Former Parent”) to support the production, marketing and sales of these phytomineral products.

Results of Operations

For the three months ended March 31, 2012 versus March 31, 2011

Revenues for the three months ended March 31, 2012 were approximately $372,000 as compared to approximately $176,000 for the three months ended March 31, 2011. Revenues were attributable to providing technology services to a licensee, Fiocruz/Bio-Manguinhos, to assist them in implementing the Company’s technology.

Research and development expense

Research and development expense for the three months ended March 31, 2012 was approximately $1,307,000 compared to approximately $1,137,000 over the comparable period in 2011, an increase of approximately $170,000. This increase primarily relates to approximately $196,000 for FhCMB to service the yellow fever vaccine contract with Fiocruz/Bio-Manguinhos using iBio’s technology. In addition, the Company incurred approximately $119,000 in outside services to a related party, to perform laboratory feasibility analyses of gene expression and protein purification and also preparation of research samples. These expenses were offest primarily by a research project (“Project 1”) that was entered into last year with FhCMB by approximately $53,000 to evaluate gene expression and protein production, focus on a series of product candidates, using the iBioLaunch platform. The focus was to determine feasibility and relative priority, for business development purposes, of several protein therapeutic candidates that are representative of

14

market classes of products. For examples, two market classes are monoclonal antibodies and plasma-derived proteins. The Company’s project with FhCMB (“Project 2”) was completed during the three months ended March 31, 2012. This project evaluated the mechanism of immune-potentiating activity of lichenase (LicKM), which is a thermostable bacterial enzyme used as a carrier molecule for vaccine antigens. The value of lichenase is as an immunomodulator. In addition, share-based compensation expense for options decreased the during the three months of 2012 as compared to 2011 by approximately $47,000 primarily due to certain options that are revalued each reporting period using the Black-Scholes option pricing model. The stock price is a component in the Black-Scholes calculation, which is used to compute fair market value. Changes in the Company’s closing stock price can result in fluctuations in share compensation results between reported periods.

General and administrative expenses

General and administrative expense for the three months ended March 31, 2012 was $1,246,000 compared to $1,927,000 for the comparable period in 2011, a decrease of approximately $681,000. The decrease is attributed primarily to reductions in share-based compensation expense for options of approximately $427,000 and share-based compensation expense for warrants of approximately $268,000. During the three months ended March 31, 2011, there were certain options granted that had shorter vesting as compared to the current period which caused the options to expense over a shorter period. The decrease in share-based compensation expense for warrants primarily represents an agreement for services that commenced during the previous period that had more of an impact on such period than the current period in conjunction with revaluing at each reporting period due to the price of the Company’s stock.

Other income (expense)

The derivative instrument liability non-cash charge for the three months ended March 31, 2012 was approximately $918,000 as compared to a non-cash charge of $144,000 for the comparable period in 2011. This resulted in an increase in a non-cash charge of approximately $774,000 for the three months ended March 31, 2012 as compared to the comparable period in 2011. The Company had issued additional warrants as a result of the anti-dilution provision as described in Note C to the notes to the unaudited condensed financial statements. In addition, the non-cash charge for the three months ended March 31, 2012 also related to the increase in the Company’s stock price at March 31, 2012 as compared to December 31, 2011. The non-cash income for the three months ended March 31, 2011 primarily relates to a decrease in the Company’s stock price at March 31, 2011 as compared to December 31, 2010. The calculation of this derivative liability is affected by factors which are subject to significant fluctuations and are not under the Company’s control. This liability resulted from warrants included in the August 2008 equity financing with an anti-dilution provision. Therefore, the resulting effect upon our net income or loss is subject to significant fluctuations and will continue to be subject to significant fluctuations until the warrants either expire in August 2013 or are exercised prior to that date. The accounting guidance applicable to these warrants requires the Company (assuming all other inputs to the pricing model remain constant) to record a non-cash charge when the Company’s stock price is rising and to record non-cash income when the Company’s stock price is falling.

Based upon the above, the net loss for the three months ended March 31, 2012 and 2011 was approximately $3,099,000 and $3,031,000 and $0.07 and $0.09 per share, respectively. The weighted average common shares outstanding – basic and diluted for the three months ended March 31, 2012 and 2011 was 45,715,762 and 32,338,587, respectively.

Results of Operations

For the nine months ended March 31, 2012 versus March 31, 2011

Revenues for the nine months ended March 31, 2012 were approximately $926,000 as compared to approximately $176,000 for the nine months ended March 31, 2011. Revenues were attributable to providing technology services to a licensee, Fiocruz/Bio-Manguinhos, to assist them in implementing the Company’s technology which commenced during the three months ended March 31, 2011.

Research and development expense

Research and development expense for the nine months ended March 31, 2012 was approximately $3,926,000 compared to approximately $1,915,000 over the comparable period in 2011, an increase of $2,011,000. This increase for the nine months ended March 31, 2012 primarily relates to two new research agreements that were entered into with FhCMB, Project 1 and Project 2 incurred more costs during the nine months than the comparable period in 2011 by approximately $806,000. Project 2 was completed during the three months ended March 31, 2012 and Project 1 commenced during the three months March 31, 2011. In addition, FhCMB was engaged to outsource the Fiocruz/Bio-Manguinhos agreement for their research and development based on their expertise to advance the yellow fever vaccine project using iBio’s technology. The increase for the nine months ended was $750,000 as compared to the comparable period in 2011. There are two $1 million obligation payments that are due each year during a five-year period and such obligations commenced in 2009. The May 2011 obligation was expensed upfront for the completion of the Pilot Plant at FhCMB as services were fully rendered through June 30, 2011. The accounting for the TTA agreement has been to expense such amounts as services are rendered. Such expense was approximately $667,000 greater for the nine months ended March 31, 2012 as compared to the comparable period in 2011. In addition, the Company incurred approximately $119,000 in outside services to a related party, to perform laboratory feasibility analyses of gene expression and protein purification and also preparation of research samples. Share-based compensation expense - options decreased for the nine months in 2012 as compared to

15

2011 by approximately $296,000, primarily due to certain options that are revalued each reporting period using the Black-Scholes option model. The stock price is a component in the Black-Scholes calculation that is used to compute fair market value. Changes in the Company’s closing stock price can result in fluctuations in share-based compensation results between reported periods.

General and administrative expenses

General and administrative expense for the nine months ended March 31, 2012 was approximately $4,180,000 compared to approximately $4,386,000 for the comparable period in 2011, a decrease of $206,000. The decrease is primarily attributed to a reduction in share-based compensation expense for warrants of approximately $939,000. Other decreases include the past consulting services by the former CFO for approximately $114,000 and public company listing fees of approximately $106,000. This was offset by an increase in share-based compensation expense for options for approximately $503,000 primarily for an option modification. In November and December 2011, the Board of Directors modified the cancellation provision of previously issued options, permitting an option holder, upon termination without cause, to exercise the vested portion of an option post-termination up to ten years after the grant date. Current period option awards granted also include this provision. The Company estimates the effect of the modification to be approximately $633,000, which will be expensed over the vesting terms, of which approximately $614,000 pertains to general and administrative expenses. For the nine months ended March 31, 2012, the amount charged to general and administrative expense was approximately $495,000. The remaining amount of $119,000 will be expensed in subsequent periods over the vesting terms. Other increases related to increases in professional fees of approximately $114,000, business travel of approximately $64,000 and in payroll and benefits of approximately $370,000. The Company hired two employees and salaries were increased primarily for the CEO and President.

Other income (expense)

The derivative instrument liability non-cash income for the nine months ended March 31, 2012 was approximately $2,873,000 as compared to a non-cash charge of approximately $4,425,000 for the comparable period in 2011. This resulted in an increase of non-cash income of approximately $7,298,000 for the nine months ended March 31, 2012 as compared to the comparable period in 2011. The non-cash income for the nine months ended March 31, 2011 of $2,873,000 is primarily due to the decrease in the Company’s stock price at March 31, 2012 as compared to June 30, 2011. However, it was also affected by the issuance of additional warrants as a result of the January 2012 equity offering due to the anti-dilution provision that was part of the August 2008 equity offering. The increase in other income – change in derivative liability of approximately $7,298,000 primarily results from decreases in the stock price at March 31, 2012 and 2011, respectively, as compared to June 30, 2011 and 2010, respectively. The calculation of this derivative liability is affected by factors, which are subject to significant fluctuations and are not under the Company’s control. This liability resulted from warrants included in the August 2008 equity financing with a down round provision. Therefore, the resulting effect upon our net income or loss is subject to significant fluctuations and will continue to be subject to significant fluctuations until the warrants either expire in August 2013 or are exercised prior to that date. The accounting guidance applicable to these warrants requires the Company (assuming all other inputs to the pricing model remain constant) to record a non-cash charge when the Company’s stock price is rising and to record non-cash income when the Company’s stock price is falling.

Based upon the above, the net loss for the nine months ended March 31, 2012 and 2011 was approximately $4,245,000 and $10,560,000 and $0.12 and $0.35 per share, respectively. The weighted average common shares outstanding – basic and diluted for the nine months ended March 31, 2012 and 2011 was 36,761,767 and 30,499,090 respectively.

Liquidity and Capital Resources

The Company has incurred losses and negative cash flows from operations since the spinoff from its Former Parent in August 2008. As of March 31, 2012, the Company had an accumulated deficit of approximately $29,975,000 and cash used from operations for the nine months ended March 31, 2012 and 2011 was approximately $4,969,000 and $4,240,000, respectively. The Company has historically financed its activities through the sale of common stock and warrants. To date, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ platform, advancing intellectual property, product candidate development, and general and administrative activities.

iBio believes it has the financial capability to meet its current obligations. In addition, the Company estimates that the cash on hand as of March 31, 2012 of approximately $6,724,000 will be adequate to fund its operations until the second calendar quarter of 2013. The Company plans to fund its further development and commercialization through licensing and partnering arrangements, which may include milestone receipts and royalties, and/or the sale of equity securities or debt. The Company cannot be certain that such funding will be available on acceptable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Further, if additional funds are raised through the issuance of equity or debt may have powers, designations, preferences or rights senior to its currently outstanding securities. If the Company is unable to raise funds when required or on acceptable terms, it may have to: a) significantly delay, scale back, or discontinue the development and/or commercialization of one or more product candidates; b) seek collaborators for product candidates at an earlier stage than would otherwise be desirable and/or on terms that are less favorable than might otherwise be available; or c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize itself and d) possibly cease operations.

16

On July 26, 2011, the Company filed with the SEC a Registration Statement on Form S-3 under the Securities Act, which was declared effective by the SEC on July 28, 2011. This Registration Statement allows the Company, from time to time, to offer and sell shares of common stock, preferred stock, warrants purchasing its securities and/or debt securities, up to a maximum aggregate amount of $100 million of such securities. The Company does not have immediate plans to further use this Shelf Registration Statement, but may in the future. The Company raised $10 million in January 2012 under this Registration Statement.

COMMITMENTS AND CONTINGENCIES

Please refer to Note F in our Annual Report on Form 10-K for the year ended June 30, 2011 under the heading Commitments and Contingencies.

Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide this information under this item.

Item 4 CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

As of March 31, 2012, the end of the period covered by this report, our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Such disclosure controls and procedures are designed to ensure that material information we must disclose in this report is recorded, processed, summarized and filed or submitted on a timely basis. Based upon that evaluation, our management, Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2012.

b) Changes in Internal Control over Financial Reporting

In February 2012, we determined that a material weakness existed in our internal control over financial reporting. This weakness resulted from the Company not considering modifications made to the terms of standard option award contracts. Additionally, the subsequent computations of the impact of such modifications included errors, which were not identified by the existing system of internal control over financial reporting. The Company’s compensating detective controls were ineffective, resulting in material adjustments to the timing and amount of stock-based compensation recognized. This weakness resulted in additions and corrections to disclosures in its December 31, 2011 Quarterly Report on Form 10-Q prior to filing. In May 2012, we determined that the Company’s compensating detective controls remain ineffective, which resulted in adjustments to the financial statements as well as additions and corrections to disclosures in this Quarterly Report on Form 10-Q prior to filing.

During the quarter ended March 31, 2012 we began remediation of this material weakness by implementing additional internal controls related to the review of financial information relating to those transactions that that are non-routine and complex. However the material weakness still exists with respect to defective controls as of the date of this filing. There have been no other changes in our internal control over financial reporting during the quarter ended March 31, 2012 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1 LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

Item 1A RISK FACTORS

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2011, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations.

Compliance with continued listing standards.

On November 4, 2011, the Company received notice from NYSE Amex LLC (the “Exchange”) that the Company was below certain of the Exchange’s continued listing standards. The Exchange indicated that its review of the Company’s Form 10-K for the year ended June 30, 2011, indicated that the Company was not in compliance with Section 1003(a)(iv), which applies if a listed company has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the company will be able to continue operations and/or meet its obligations as they mature.

The Company was afforded the opportunity to submit a plan of compliance to the Exchange by November 28, 2011 that would demonstrate the Company’s ability to regain compliance with Section 1003(a)(iv) of the Company Guide by January 25, 2012.

The Company provided the Exchange with a satisfactory plan by November 28, 2011, to show that it would be able to return to compliance with Section 1003(a)(iv) of the Company Guide by January 25, 2012. Based upon subsequent submissions by the Company to the Exchange on January 27, 2012, the Exchange confirmed that the listing deficiency was resolved.

Internal Controls

As detailed in Part I, Item 4(b) above, the Company determined in February 2012 that a material weakness existed in its internal control over financial reporting, and the Company determined in May 2012 that certain controls remain ineffective. Failure in the remediation of this weakness could diminish the Company’s ability to meet its financial reporting obligations in an accurate and timely manner.

Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

17

Item 3 DEFAULTS UPON SENIOR SECURITIES

None.

Item 4 MINE SAFETY DISCLOSURES

Not applicable.

Item 5 OTHER INFORMATION

None.

Item 6 EXHIBITS
Exhibit Number

31.1	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
31.2	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
32.2	Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
101.INS	XBRL Instance Document ‡
101.SCH	XBRL Taxonomy Extension Schema Document‡
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Extension Definition
101.LAB	XBRL Taxonomy Extension Label Linkbase Document‡
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document‡

‡ Pursuant to applicable securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

18

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

	iBio, Inc.
Date: May 15, 2012	By:	/s/ Robert B. Kay
	Robert B. Kay,
	Chief Executive Officer
Date: May 15, 2012	By:	/s/ Douglas Beck, CPA
	Douglas Beck, CPA
	Chief Financial Officer

19